Presentation (CTI)

OBJECTIVES: In preparation of launching a therapy for obesity and MASH, BI commissioned CF to review the obesity landscape and, to the extent possible, the MASH landscape to support understanding of: 1.how to shape a receptive market 2.what evidence gaps need to be discussed in light of that
METHODS: CF produced a report combining public data and DARS resources (e.g., Hospital Episode Statistics) to assess disease burden, health impact, resource use, and costs. Findings showed people with obesity use hospital resources three times more than others. We also conducted research and stakeholder interviews to explore policy, patient pathways, market dynamics, and value proposition needs.
RESULTS: The report highlights how obesity is growing epidemic despite long-term efforts to tackle prevalence. MASH also represents a significant opportunity given growing prevalence and a lack of drugs currently on the market with MASH specification. However, the changing market for these drugs in the UK - driven by shifting NHS strategic priorities, the pharma pipeline, strict regulatory processes and policy changes - necessitate novel approaches to drug development and launch to enable success.
CONCLUSIONS: We created a framework to guide market access for new drugs, focusing on: 1) Patient - Alignment between patient needs and the system; 2) Product - Value proposition, benefits, and policy fit; 3) Reimbursement - Strong evidence of clinical, economic, workforce, and equality impact; 4) Communication - Clear messaging to target audiences and stakeholders; 5) Pathway - Whole pathway impact on patients, staff, and system; 6) Delivery - Reaching patients via digital or traditional routes with training and improvement; 7) Data - Early evidence generation and tracking uptake; 8) Finance - Alignment to national strategies, policies, and funding. Commissioning - Agreement for product to add to supply chain and into formulary as part of model of care 10. Addressing unwarranted variation